Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: A report of six cases

British Journal of Dermatology

Volumn 155, Issue 2, 2006, Pages 451-454

  Ulrich, C ^a   Busch, J O ^b   Meyer, T ^c   Nindl, I ^a   Schmook, T ^a   Sterry, W ^a   Stockfleth, E ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c IPM   (Germany)

Author keywords

Actinic keratoses; Imiquimod; Immune response modifier; Organ transplant patients; Skin cancer

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMIQUIMOD; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EROSION; GRAFT VERSUS HOST REACTION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER GRAFT; LUNG; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; SCAR FORMATION; WOUND INFECTION;

ADMINISTRATION, CUTANEOUS; AGED; AMINOQUINOLINES; BIOLOGICAL RESPONSE MODIFIERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; KERATOSIS; MALE; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; PILOT PROJECTS; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS; TRANSPLANTS; TREATMENT OUTCOME;

EID: 33644904180     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07233.x     Document Type: Article

References (14)

1. Stockfleth E, Ulrich C, Meyer T et al. Skin diseases following organ transplantation - risk factors and new therapeutic approaches. Transplant Proc 2001; 33:1848-53.
2. Euvrard S, Kanitakis J, Pouteil-Noble C. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33:222-9.
3. Boyle J, Briggs JD, MacKie RM et al. Cancer, warts and sunshine in renal transplant patients: a case-control study. Lancet 1984; i:702-4.
4. Burnet M. Immunological factors in the process of carcinogenesis. Br Med Bull 1964; 20:154-8.
5. Boyd AS, Stasko T, Cameron GS. Histologic features of actinic keratoses in solid organ transplant recipients and healthy controls. J Am Acad Dermatol 2001; 45:217-21.
6. Penn I. Cancer is a complication of severe immunosuppresion. Surg Gynecol Obstet 1986; 162:603-10.
7. Stockfleth E, Meyer T, Benninghoff B. Successful treatment of actinic keratoses with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144:1050-3.
8. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27:561-4.
9. Feldman SR, Fleischer AB, Williford PM et al. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol 1999; 40:43-7.
10. Jeffes EW, Tang EH. Actinic keratoses. Current treatment options. Am J Clin Dermatol 2000; 1:167-79.
11. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58:365-72.
12. Hemmi H, Kaisho T, Takeuchi O et al. Small antiviral compounds activate immune cells via the TLR7MyD88-dependent signal pathway. Nat Immunol 2002; 3:196-200.
13. Jackson S, Harwood C, Thomas M et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14:3065-73.
14. Bouwes Bavinck JN, Feltkamp M, Struijk L., ter Schegget J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Invest Dermatol Symp Proc 2001; 6:207-11.